Abstract
Alpha-methyl-para-tyrosine (AMPT) temporarily inhibits tyrosine hydroxylase, the rate limiting step in the dopamine biosynthesis cascade. AMPT has been approved for clinical use in phaeochromocytoma in 1979. Recently however, AMPT has been increasingly employed as a pharmacological challenge in acute dopamine depletion studies including neuroimaging studies. The use of this exciting challenge technique allows us to increase our understanding of dopaminergic neurotransmission in the brain. In addition, there have been clinical reports that AMPT may be useful to treat movement disorders like dystonia, dyskinesia and Huntingtons chorea, psychiatric disorders like mania, psychosis, obsessive compulsive disorder and substance abuse as well as behavioral problems in 22q11 deletion syndrome. In this review we will discuss the effects of AMPT in challenge studies that have been reported in humans. Furthermore we will review all studies reporting therapeutic effects of AMPT in neuropsychiatric disorders and adverse effects associated with AMPT use reported in both challenge and therapeutic research.
Keywords: Alpha-methyl-para-tyrosine, AMPT, dopamine, depletion, challenge, treatment, catecholamine
Central Nervous System Agents in Medicinal Chemistry
Title: Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review
Volume: 8 Issue: 4
Author(s): Oswald J.N. Bloemen, M. B. de Koning, E. Boot, J. Booij and T.A. M.J. van Amelsvoort
Affiliation:
Keywords: Alpha-methyl-para-tyrosine, AMPT, dopamine, depletion, challenge, treatment, catecholamine
Abstract: Alpha-methyl-para-tyrosine (AMPT) temporarily inhibits tyrosine hydroxylase, the rate limiting step in the dopamine biosynthesis cascade. AMPT has been approved for clinical use in phaeochromocytoma in 1979. Recently however, AMPT has been increasingly employed as a pharmacological challenge in acute dopamine depletion studies including neuroimaging studies. The use of this exciting challenge technique allows us to increase our understanding of dopaminergic neurotransmission in the brain. In addition, there have been clinical reports that AMPT may be useful to treat movement disorders like dystonia, dyskinesia and Huntingtons chorea, psychiatric disorders like mania, psychosis, obsessive compulsive disorder and substance abuse as well as behavioral problems in 22q11 deletion syndrome. In this review we will discuss the effects of AMPT in challenge studies that have been reported in humans. Furthermore we will review all studies reporting therapeutic effects of AMPT in neuropsychiatric disorders and adverse effects associated with AMPT use reported in both challenge and therapeutic research.
Export Options
About this article
Cite this article as:
Bloemen J.N. Oswald, de Koning B. M., Boot E., Booij J. and van Amelsvoort M.J. T.A., Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (4) . https://dx.doi.org/10.2174/187152408786848102
DOI https://dx.doi.org/10.2174/187152408786848102 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Application of Network Descriptions for Understanding Conformational Changes and Protonation States of ABC Transporters
Current Pharmaceutical Design Insights into Airway Infections by Enterococci: A Review
Recent Patents on Anti-Infective Drug Discovery Drugs and Aggression
Recent Patents on CNS Drug Discovery (Discontinued) Type 1 Diabetes Mellitus - Risk Factor for Cardiovascular Disease Morbidity and Mortality
Current Diabetes Reviews Structure and Function of the Acidic Ribosomal Stalk Proteins
Current Protein & Peptide Science A Brief History of ‘Lone’ Atrial Fibrillation: From ‘A Peculiar Pulse Irregularity’ to a Modern Public Health Concern
Current Pharmaceutical Design Neurobiology of Sleep Disturbances in Neurodegenerative Disorders
Current Pharmaceutical Design Amino Acid Metabolic Routes in Trypanosoma cruzi: Possible Therapeutic Targets Against Chagas; Disease
Current Drug Targets - Infectious Disorders Kappa Opioids, Salvinorin A and Major Depressive Disorder
Current Neuropharmacology Design Strategies of Novel NNRTIs to Overcome Drug Resistance
Current Medicinal Chemistry Nanotechnology Driven Approaches for the Management of Parkinson’s Disease: Current Status and Future Perspectives
Current Drug Metabolism Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
Current Medicinal Chemistry L-Type Calcium Channels
Current Pharmaceutical Design Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology Mucoadhesive Polymers for Delivery of Drugs to the Oral Cavity
Recent Patents on Drug Delivery & Formulation Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Female Infertility and Assisted Reproduction: Impact of Oxidative Stress-- An Update
Current Women`s Health Reviews Mathematical Models of Blood Coagulation and Platelet Adhesion: Clinical Applications
Current Pharmaceutical Design Editorial: [Exciting Discoveries About New p53 Target Genes, Cancer Drugs and Diagnostic Tools, and Mechanisms of Various Human Diseases]
Current Molecular Medicine Paraneoplastic Neurological Syndromes - Diagnosis and Management
Current Pharmaceutical Design